世界の抗体薬物複合体(ADC)市場インサイト及び予測(~2026年)

【英語タイトル】Global Antibody Drug Conjugates (ADCs) Market Size, Status and Forecast 2020-2026

QYResearchが出版した調査資料(QYR20NV10862)・商品コード:QYR20NV10862
・発行会社(調査会社):QYResearch
・発行日:2020年11月(※2024年版があります。お問い合わせください)
・ページ数:94
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートは抗体薬物複合体(ADC)の世界市場について調査・分析した資料です。種類別(シアトルジェネティクス技術、イミュノジェン技術、イミュノメディクス技術)の市場規模、用途別(病院、診療所、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別抗体薬物複合体(ADC)の競争状況、市場シェア
・世界の抗体薬物複合体(ADC)市場:種類別市場規模 2015年-2020年(シアトルジェネティクス技術、イミュノジェン技術、イミュノメディクス技術)
・世界の抗体薬物複合体(ADC)市場:種類別市場規模予測 2021年-2026年(シアトルジェネティクス技術、イミュノジェン技術、イミュノメディクス技術)
・世界の抗体薬物複合体(ADC)市場:用途別市場規模 2015年-2020年(病院、診療所、その他)
・世界の抗体薬物複合体(ADC)市場:用途別市場規模予測 2021年-2026年(病院、診療所、その他)
・北米の抗体薬物複合体(ADC)市場分析:米国、カナダ
・ヨーロッパの抗体薬物複合体(ADC)市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの抗体薬物複合体(ADC)市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の抗体薬物複合体(ADC)市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの抗体薬物複合体(ADC)市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Roche、Pfizer、Novartis、Genmab、Bayer、Seattle Genetics、Takeda Pharmaceuticals、AbbVie、AbGenomics、ADC Therapeutics、Astellas Pharma、Kairos Therapeutics
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.

Market Analysis and Insights: Global Antibody Drug Conjugates (ADCs) Market
The global Antibody Drug Conjugates (ADCs) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Antibody Drug Conjugates (ADCs) Scope and Market Size
Antibody Drug Conjugates (ADCs) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugates (ADCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics

Market segment by Type, the product can be split into
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Market segment by Application, split into
Hospital
Clinics
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Antibody Drug Conjugates (ADCs) Revenue
1.4 Market by Type
1.4.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Seattle Genetics Technology
1.4.3 ImmunoGen Technology
1.4.4 Immunomedics Technology
1.5 Market by Application
1.5.1 Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Antibody Drug Conjugates (ADCs) Market Perspective (2015-2026)
2.2 Global Antibody Drug Conjugates (ADCs) Growth Trends by Regions
2.2.1 Antibody Drug Conjugates (ADCs) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Antibody Drug Conjugates (ADCs) Historic Market Share by Regions (2015-2020)
2.2.3 Antibody Drug Conjugates (ADCs) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Antibody Drug Conjugates (ADCs) Market Growth Strategy
2.3.6 Primary Interviews with Key Antibody Drug Conjugates (ADCs) Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugates (ADCs) Players by Market Size
3.1.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue (2015-2020)
3.1.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2015-2020)
3.1.3 Global Antibody Drug Conjugates (ADCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio
3.2.1 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugates (ADCs) Revenue in 2019
3.3 Antibody Drug Conjugates (ADCs) Key Players Head office and Area Served
3.4 Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
3.5 Date of Enter into Antibody Drug Conjugates (ADCs) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Type (2015-2020)
4.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)
5.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Antibody Drug Conjugates (ADCs) Market Size (2015-2020)
6.2 Antibody Drug Conjugates (ADCs) Key Players in North America (2019-2020)
6.3 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
6.4 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)

7 Europe
7.1 Europe Antibody Drug Conjugates (ADCs) Market Size (2015-2020)
7.2 Antibody Drug Conjugates (ADCs) Key Players in Europe (2019-2020)
7.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
7.4 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)

8 China
8.1 China Antibody Drug Conjugates (ADCs) Market Size (2015-2020)
8.2 Antibody Drug Conjugates (ADCs) Key Players in China (2019-2020)
8.3 China Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
8.4 China Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)

9 Japan
9.1 Japan Antibody Drug Conjugates (ADCs) Market Size (2015-2020)
9.2 Antibody Drug Conjugates (ADCs) Key Players in Japan (2019-2020)
9.3 Japan Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
9.4 Japan Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size (2015-2020)
10.2 Antibody Drug Conjugates (ADCs) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
10.4 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)

11 India
11.1 India Antibody Drug Conjugates (ADCs) Market Size (2015-2020)
11.2 Antibody Drug Conjugates (ADCs) Key Players in India (2019-2020)
11.3 India Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
11.4 India Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Antibody Drug Conjugates (ADCs) Market Size (2015-2020)
12.2 Antibody Drug Conjugates (ADCs) Key Players in Central & South America (2019-2020)
12.3 Central & South America Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
12.4 Central & South America Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Roche
13.1.1 Roche Company Details
13.1.2 Roche Business Overview
13.1.3 Roche Antibody Drug Conjugates (ADCs) Introduction
13.1.4 Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020))
13.1.5 Roche Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview
13.2.3 Pfizer Antibody Drug Conjugates (ADCs) Introduction
13.2.4 Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Antibody Drug Conjugates (ADCs) Introduction
13.3.4 Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Genmab
13.4.1 Genmab Company Details
13.4.2 Genmab Business Overview
13.4.3 Genmab Antibody Drug Conjugates (ADCs) Introduction
13.4.4 Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.4.5 Genmab Recent Development
13.5 Bayer
13.5.1 Bayer Company Details
13.5.2 Bayer Business Overview
13.5.3 Bayer Antibody Drug Conjugates (ADCs) Introduction
13.5.4 Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.5.5 Bayer Recent Development
13.6 Seattle Genetics
13.6.1 Seattle Genetics Company Details
13.6.2 Seattle Genetics Business Overview
13.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Introduction
13.6.4 Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.6.5 Seattle Genetics Recent Development
13.7 Takeda Pharmaceuticals
13.7.1 Takeda Pharmaceuticals Company Details
13.7.2 Takeda Pharmaceuticals Business Overview
13.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Introduction
13.7.4 Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.7.5 Takeda Pharmaceuticals Recent Development
13.8 AbbVie
13.8.1 AbbVie Company Details
13.8.2 AbbVie Business Overview
13.8.3 AbbVie Antibody Drug Conjugates (ADCs) Introduction
13.8.4 AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.8.5 AbbVie Recent Development
13.9 AbGenomics
13.9.1 AbGenomics Company Details
13.9.2 AbGenomics Business Overview
13.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Introduction
13.9.4 AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.9.5 AbGenomics Recent Development
13.10 ADC Therapeutics
13.10.1 ADC Therapeutics Company Details
13.10.2 ADC Therapeutics Business Overview
13.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Introduction
13.10.4 ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
13.10.5 ADC Therapeutics Recent Development
13.11 Astellas Pharma
10.11.1 Astellas Pharma Company Details
10.11.2 Astellas Pharma Business Overview
10.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Introduction
10.11.4 Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
10.11.5 Astellas Pharma Recent Development
13.12 Kairos Therapeutics
10.12.1 Kairos Therapeutics Company Details
10.12.2 Kairos Therapeutics Business Overview
10.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Introduction
10.12.4 Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
10.12.5 Kairos Therapeutics Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Antibody Drug Conjugates (ADCs) Key Market Segments
Table 2. Key Players Covered: Ranking by Antibody Drug Conjugates (ADCs) Revenue
Table 3. Ranking of Global Top Antibody Drug Conjugates (ADCs) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Seattle Genetics Technology
Table 6. Key Players of ImmunoGen Technology
Table 7. Key Players of Immunomedics Technology
Table 8. Global Antibody Drug Conjugates (ADCs) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Antibody Drug Conjugates (ADCs) Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Antibody Drug Conjugates (ADCs) Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2015-2020)
Table 12. Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Antibody Drug Conjugates (ADCs) Market Growth Strategy
Table 18. Main Points Interviewed from Key Antibody Drug Conjugates (ADCs) Players
Table 19. Global Antibody Drug Conjugates (ADCs) Revenue by Players (2015-2020) (Million US$)
Table 20. Global Antibody Drug Conjugates (ADCs) Market Share by Players (2015-2020)
Table 21. Global Top Antibody Drug Conjugates (ADCs) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugates (ADCs) as of 2019)
Table 22. Global Antibody Drug Conjugates (ADCs) by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
Table 25. Date of Enter into Antibody Drug Conjugates (ADCs) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 28. Global Antibody Drug Conjugates (ADCs) Market Size Share by Type (2015-2020)
Table 29. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2021-2026)
Table 30. Global Antibody Drug Conjugates (ADCs) Market Size Share by Application (2015-2020)
Table 31. Global Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 32. Global Antibody Drug Conjugates (ADCs) Market Size Share by Application (2021-2026)
Table 33. North America Key Players Antibody Drug Conjugates (ADCs) Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Antibody Drug Conjugates (ADCs) Market Share (2019-2020)
Table 35. North America Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 36. North America Antibody Drug Conjugates (ADCs) Market Share by Type (2015-2020)
Table 37. North America Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 38. North America Antibody Drug Conjugates (ADCs) Market Share by Application (2015-2020)
Table 39. Europe Key Players Antibody Drug Conjugates (ADCs) Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Antibody Drug Conjugates (ADCs) Market Share (2019-2020)
Table 41. Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Antibody Drug Conjugates (ADCs) Market Share by Type (2015-2020)
Table 43. Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Antibody Drug Conjugates (ADCs) Market Share by Application (2015-2020)
Table 45. China Key Players Antibody Drug Conjugates (ADCs) Revenue (2019-2020) (Million US$)
Table 46. China Key Players Antibody Drug Conjugates (ADCs) Market Share (2019-2020)
Table 47. China Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 48. China Antibody Drug Conjugates (ADCs) Market Share by Type (2015-2020)
Table 49. China Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 50. China Antibody Drug Conjugates (ADCs) Market Share by Application (2015-2020)
Table 51. Japan Key Players Antibody Drug Conjugates (ADCs) Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Antibody Drug Conjugates (ADCs) Market Share (2019-2020)
Table 53. Japan Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Antibody Drug Conjugates (ADCs) Market Share by Type (2015-2020)
Table 55. Japan Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Antibody Drug Conjugates (ADCs) Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Antibody Drug Conjugates (ADCs) Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Antibody Drug Conjugates (ADCs) Market Share (2019-2020)
Table 59. Southeast Asia Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Antibody Drug Conjugates (ADCs) Market Share by Type (2015-2020)
Table 61. Southeast Asia Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Antibody Drug Conjugates (ADCs) Market Share by Application (2015-2020)
Table 63. India Key Players Antibody Drug Conjugates (ADCs) Revenue (2019-2020) (Million US$)
Table 64. India Key Players Antibody Drug Conjugates (ADCs) Market Share (2019-2020)
Table 65. India Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 66. India Antibody Drug Conjugates (ADCs) Market Share by Type (2015-2020)
Table 67. India Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 68. India Antibody Drug Conjugates (ADCs) Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Antibody Drug Conjugates (ADCs) Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Antibody Drug Conjugates (ADCs) Market Share (2019-2020)
Table 71. Central & South America Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Antibody Drug Conjugates (ADCs) Market Share by Type (2015-2020)
Table 73. Central & South America Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Antibody Drug Conjugates (ADCs) Market Share by Application (2015-2020)
Table 75. Roche Company Details
Table 76. Roche Business Overview
Table 77. Roche Product
Table 78. Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 79. Roche Recent Development
Table 80. Pfizer Company Details
Table 81. Pfizer Business Overview
Table 82. Pfizer Product
Table 83. Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 84. Pfizer Recent Development
Table 85. Novartis Company Details
Table 86. Novartis Business Overview
Table 87. Novartis Product
Table 88. Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 89. Novartis Recent Development
Table 90. Genmab Company Details
Table 91. Genmab Business Overview
Table 92. Genmab Product
Table 93. Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 94. Genmab Recent Development
Table 95. Bayer Company Details
Table 96. Bayer Business Overview
Table 97. Bayer Product
Table 98. Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 99. Bayer Recent Development
Table 100. Seattle Genetics Company Details
Table 101. Seattle Genetics Business Overview
Table 102. Seattle Genetics Product
Table 103. Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 104. Seattle Genetics Recent Development
Table 105. Takeda Pharmaceuticals Company Details
Table 106. Takeda Pharmaceuticals Business Overview
Table 107. Takeda Pharmaceuticals Product
Table 108. Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 109. Takeda Pharmaceuticals Recent Development
Table 110. AbbVie Business Overview
Table 111. AbbVie Product
Table 112. AbbVie Company Details
Table 113. AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 114. AbbVie Recent Development
Table 115. AbGenomics Company Details
Table 116. AbGenomics Business Overview
Table 117. AbGenomics Product
Table 118. AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 119. AbGenomics Recent Development
Table 120. ADC Therapeutics Company Details
Table 121. ADC Therapeutics Business Overview
Table 122. ADC Therapeutics Product
Table 123. ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 124. ADC Therapeutics Recent Development
Table 125. Astellas Pharma Company Details
Table 126. Astellas Pharma Business Overview
Table 127. Astellas Pharma Product
Table 128. Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 129. Astellas Pharma Recent Development
Table 130. Kairos Therapeutics Company Details
Table 131. Kairos Therapeutics Business Overview
Table 132. Kairos Therapeutics Product
Table 133. Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020) (Million US$)
Table 134. Kairos Therapeutics Recent Development
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody Drug Conjugates (ADCs) Market Share by Type: 2020 VS 2026
Figure 2. Seattle Genetics Technology Features
Figure 3. ImmunoGen Technology Features
Figure 4. Immunomedics Technology Features
Figure 5. Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2020 VS 2026
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Antibody Drug Conjugates (ADCs) Report Years Considered
Figure 10. Global Antibody Drug Conjugates (ADCs) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Antibody Drug Conjugates (ADCs) Market Share by Regions: 2020 VS 2026
Figure 12. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Antibody Drug Conjugates (ADCs) Market Share by Players in 2019
Figure 15. Global Top Antibody Drug Conjugates (ADCs) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugates (ADCs) as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Antibody Drug Conjugates (ADCs) Revenue in 2019
Figure 17. North America Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed


【掲載企業】

Roche、Pfizer、Novartis、Genmab、Bayer、Seattle Genetics、Takeda Pharmaceuticals、AbbVie、AbGenomics、ADC Therapeutics、Astellas Pharma、Kairos Therapeutics

★調査レポート[世界の抗体薬物複合体(ADC)市場インサイト及び予測(~2026年)] (コード:QYR20NV10862)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の抗体薬物複合体(ADC)市場インサイト及び予測(~2026年)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆